| Prev Close | 85.35 |
| Open | 85.57 |
| Day Low/High | 85.11 / 85.99 |
| 52 Wk Low/High | 33.03 / 53.97 |
| Volume | 250.35K |
| Avg Volume | 520.70K |
| Exchange | NASDAQ |
| Shares Outstanding | 51.94M |
| Market Cap | 4.45B |
| EPS | 6.10 |
| P/E Ratio | 13.81 |
| Div & Yield | N.A. (N.A) |
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 15th Annual Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York on Tuesday, September 12, 2017 at 1:30 p.
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers in Maastricht, The Netherlands evaluated the performance of Masimo iSpO 2 ® Rx in screening newborns for...
Masimo (NASDAQ:MASI) announced today the findings of a recently published study in which researchers in New Delhi, India evaluated the utility of Masimo SpHb ®, noninvasive, continuous hemoglobin measurement,...
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi ®, a noninvasive and continuous...
Masimo (NASDAQ:MASI) announced today that the Dubai Health Authority (DHA), the government organization that oversees the healthcare systems of Dubai, is augmenting its current inventory of Masimo equipment and...
Jim Cramer is bullish on Philip Morris, 3M and Becton Dickinson; but he's bearish on Blue Apron and Puma Biotechnology.
Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Cairo University in Egypt evaluated the performance of Masimo SpHb ®, noninvasive, continuous hemoglobin...
Masimo (NASDAQ: MASI) today announced its financial results for the second quarter ended July 1, 2017.
Masimo (NASDAQ: MASI) announced today that researchers at the Tokyo Women's Medical University, Department of Anesthesiology, in Japan have published a study investigating the measurement of respiration rate in...
Masimo (NASDAQ: MASI) announced today the CE marking of RPVi™, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during one or more respiratory cycles.
Masimo (NASDAQ: MASI) announced today that it will release financial results for the second quarter ended July 1, 2017, after the market closes on Wednesday, August 2, 2017.
The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 396,166 share increase in total short interest for Masimo Corp. , to 2,825,251, an increase of 16.31% since 06/15/2017.
Masimo (NASDAQ: MASI) announced today the CE marking of the rainbow ® Super DCI ®-mini sensor, a reusable spot-check sensor that features Masimo SET ® Measure-through Motion and Low Perfusion™...
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2017 in Geneva, Switzerland.
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the recent International Anesthesia Research Society (IARS) Annual Meeting in Washington, DC.
Masimo (NASDAQ:MASI) announced today, in conjunction with its CE marking, the limited market release of the Spot-Check Rad-67™ Handheld Pulse CO-Oximeter ®.
Masimo (NASDAQ: MASI) and Mdoloris Medical Systems announced today a Masimo Open Connect™ (MOC) partnership for the Root ® Open Architecture Patient Monitoring and Connectivity Hub, in which Mdoloris is...
Masimo (NASDAQ:MASI) announced today FDA 510(k) clearance for the pediatric indication for O3™ regional oximetry with the O3 pediatric sensor.
The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 765,702 share decrease in total short interest for Masimo Corp. , to 2,329,761, a decrease of 24.74% since 04/28/2017.
Masimo (NASDAQ: MASI) announced today the full market release of Early Warning Score (EWS) on the Root ® patient monitoring and connectivity hub.
Midmark Corporation, a leading medical solutions provider for ambulatory care, and Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, today announced a partnership focused on improving...
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the International Anesthesia Research Society (IARS) Annual Meeting in Washington, DC.
Joe Kiani, founder, chairman and CEO of Masimo, tells Jim Cramer about his company's great earnings.
Jim Cramer lays out next week's game plan: Tech stocks look strong, but same-store sales are sinking retail.
Masimo (NASDAQ:MASI) today announced the introduction of Rad-G™, a combined pulse oximeter designed primarily for use in pneumonia screening and spot-checking of oxygen saturation (SpO 2) in low-resource...
Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended April 1, 2017.
